Akers Biosciences Inc. (AKER)’s Financial Results Comparing With Precision Therapeutics Inc. (NASDAQ:AIPT)

Akers Biosciences Inc. (NASDAQ:AKER) and Precision Therapeutics Inc. (NASDAQ:AIPT) are two firms in the Medical Instruments & Supplies that compete against each other. Below is a comparison of their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akers Biosciences Inc. 1.98M 3.51 9.91M -0.98 0.00
Precision Therapeutics Inc. 1.26M 15.64 11.62M -0.78 0.00

Demonstrates Akers Biosciences Inc. and Precision Therapeutics Inc. earnings per share (EPS), top-line revenue and valuation.


Table 2 represents Akers Biosciences Inc. (NASDAQ:AKER) and Precision Therapeutics Inc. (NASDAQ:AIPT)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Akers Biosciences Inc. -500.51% -121.3% -100.3%
Precision Therapeutics Inc. -922.22% -346.2% -211%

Risk & Volatility

Akers Biosciences Inc.’s -0.95 beta indicates that its volatility is 195.00% less volatile than that of Standard & Poor’s 500. Competitively, Precision Therapeutics Inc.’s 95.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 1.95 beta.


Akers Biosciences Inc. has a Current Ratio of 3.4 and a Quick Ratio of 3.1. Competitively, Precision Therapeutics Inc.’s Current Ratio is 0.4 and has 0.3 Quick Ratio. Akers Biosciences Inc.’s better ability to pay short and long-term obligations than Precision Therapeutics Inc.

Insider and Institutional Ownership

The shares of both Akers Biosciences Inc. and Precision Therapeutics Inc. are owned by institutional investors at 8.7% and 3.1% respectively. About 0.2% of Akers Biosciences Inc.’s share are owned by insiders. Competitively, Precision Therapeutics Inc. has 2.2% of it’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Akers Biosciences Inc. -1.36% -7.5% -19.57% -68.27% -78.54% -33.45%
Precision Therapeutics Inc. -11.43% -15.65% -37.37% -33.33% -36.08% 0.14%

For the past year Akers Biosciences Inc. has -33.45% weaker performance while Precision Therapeutics Inc. has 0.14% stronger performance.


On 7 of the 10 factors Akers Biosciences Inc. beats Precision Therapeutics Inc.

Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The company’s marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ‘Check’, a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company’s pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth ‘Check’, a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.